Navigation Links
Prodigy Diabetes Care and OK Biotech Align Ownership

CHARLOTTE, N.C., April 16, 2013 /PRNewswire/ -- Prodigy Diabetes Care (Prodigy) announced today that its current manufacturing partner, OK Biotech Co., Ltd., (OK Biotech) has purchased a minority stake in the company, and Prodigy acquired substantial ownership of OK Biotech's publicly traded shares.

After a four-year contractual relationship, both parties agreed that a strategic partnership delivers the most benefit to their customers and patients. Prodigy and OK Biotech developed this new relationship in anticipation of the demand of a consolidated customer base for high-volume, lower cost diabetes testing supplies.

Beginning July 1, 2013, Centers for Medicare and Medicaid Services will implement its new contracts for National Mail Order Competitive Bidding for diabetes testing supplies. This program reduced reimbursement rates for diabetes supplies by 72 percent. The federal government awarded contracts to 23 mail order patient providers, eliminating thousands of suppliers from the market. These cuts strike a blow to manufacturers whose products retail at four or five times the Medicare reimbursement rate.

Prodigy and OK Biotech's new alignment ensures that providers have the capacity to meet the increases in volume and the need for lower priced quality products. Overlapping ownership interests ensure Prodigy and OK Biotech can cooperatively offer the best pricing solutions to accommodate the lower reimbursement rates. 

"We knew we needed to take an aggressive approach to the new Medicare program," said Rick Admani , Prodigy COO.  "Once the Medicare program announcement was made, we took it as an opportunity to strengthen our affiliation with OK Biotech and meet with many of the bid winners to offer them our best pricing.  The responses we've received have been overwhelmingly positive, and we are now under contract with most of the largest bid winners. It is already apparent that our alignment with OK Biotech will help us expand even more rapidly while providing the same quality products and services."

Though the competitive bidding process was originally limited to mail order suppliers, a provision in the fiscal cliff legislation reduced the retail reimbursement for diabetes test strips to the new lower rate that applies to mail order products.  Prodigy has offered retailers the same solutions as their mail order counterparts, providing high quality diabetes testing supplies at a cost that will still generate a profit.

"Continuing our partnership with Prodigy builds on our current industry standing as a leader," said James Lai, OK Biotech president. "We invested a substantial amount of money in Prodigy and in our new manufacturing facility to show our commitment to this market. The alignment of Prodigy's quality design products with our proven manufacturing capabilities and capacity will enable us to deliver four billion test strips annually at a favorable price point for our clients."

About Prodigy Diabetes Care
Prodigy Diabetes Care, LLC is a privately owned distributor of diabetes testing supplies. Established by principals with more than 45 collective years in the medical supplies industry, Prodigy distributes its products throughout the U.S. and world. Located in Charlotte, N.C., Prodigy now employs people nationwide. Prodigy has been commended for its growth and success by the Department of Commerce, the City of Charlotte and Inc. Magazine, and its innovative products have been recognized by the National Federation of the Blind and the American Foundation for the Blind.

About OK Biotech
OK Biotech Co., Ltd., located in Hsinchu, Taiwan, is a publicly traded company on the Taiwan exchange.  OK Biotech has experienced substantial growth since its establishment in 2005 due to its high quality manufacturing processes.  Anticipating the rapid growth in demand for its products, OK Biotech dramatically increased its production capabilities by moving to its new manufacturing and headquarters facility during March, 2013. Focused on Quality, Concern for Patients, Constancy in the Market and Leadership, OK Biotech is poised to continue as a leading manufacturer of diabetes testing supplies.

SOURCE Prodigy Diabetes Care
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
2. Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
5. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
6. CASiGEN Pharma Receives A World-wide Exclusive License From GIBH To Bring New Potential Diabetes Treatments To The Global Market
7. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
8. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
9. Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
11. JDRF and BD Collaborate to Develop More Accurate and Reliable Glucose Monitoring Devices for People with Type 1 Diabetes
Post Your Comments:
(Date:11/30/2015)... Calif. , Nov. 30, 2015 /PRNewswire/ ... the norm in U.S. medical imaging is ... increasingly popular accountable care payer-provider contracts are ... and, in their wake, alter provider-vendor relationships. ... payments will push forward new purchasing frameworks ...
(Date:11/30/2015)... JERUSALEM , Nov. 30, 2015 Oramed ... company focused on the development of oral drug delivery ... investment agreements valued at up to $50,000,000 with Hefei Tianhui Incubator of ... Oramed,s oral insulin capsule, ORMD-0801, in China ... Macau . The agreements were signed ...
(Date:11/30/2015)... N.H. , Nov. 30, 2015 ... that it will feature its latest solutions for ... early identification of cancer at the Radiological Society ... Chicago from November 29 ... recent product advances including iReveal®, an automated breast ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... California-based i2i Systems, a pioneer defining ... Michigan-based Family Health Center (FHC) has selected i2iTracks as their population health management ... the largest Affordable Care Act grant for Federally Qualified Health Centers in the ...
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... two new additions to its industry-leading suite of automated breast density assessment ... North America (RSNA) meeting, November 29-December 4, 2015 (South Hall booth #2377). ...
(Date:11/30/2015)... New York, New York (PRWEB) , ... November 30, 2015 , ... ... at the Greater New York Dental Meeting. Their Ecosystem empowers dentists to make complex ... Dentists who visit the booth will receive a free fee survey with 10 procedures ...
(Date:11/30/2015)... ... 2015 , ... Scott Newman MD, FACS of New York’s ... surgeons in the New York City area to utilize the new, non-invasive SculpSure™ ... laser treatment for fat loss in the abdomen, flanks, and other areas that ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... healthcare professionals worldwide today released the results of a survey of educational needs ... and Africa found a growing global demand for high quality online and face-to-face ...
Breaking Medicine News(10 mins):